|
Eveia’s plan is to develop a series of immunoassay systems for release into the Research Market and the Clinical Diagnostic Market. At least two systems are envisioned for the Clinical Diagnostic Market, one to serve low to mid volume small hospitals and physicians office laboratories (POL) and a second to serve the high volume large hospitals and reference laboratories. Eveia is actively seeking corporate partnerships to rapidly enter into these markets.
- Research Market - Life Science market including; pharmaceutical, diagnostic, academic and government laboratories.
- Clinical Market - Central clinical laboratories for routine high throughput testing and POC clinical laboratories in satellite and physician’s office laboratories.
The test menu will include high volume clinical diagnostics such as TSH, PSA, cardiac markers etc. as well as ultra-sensitive assays for both the clinical and research markets.
Tests for the Clinical Markets include:
- Cancer - diagnostics, monitoring therapy, early screening.
- Endocrinology - ultra-sensitive testing for thyroid, adrenal, pituitary, ovarian and testicular disorders.
- Autoimmune – monitoring therapy, disease progression.
- Cardiovascular/Diabetes - monitoring therapy, disease progression.
- Infectious Disease - therapy selection e.g. MRSA.
- Routine Serology.
|
